Open AccessProton Pump Inhibitor Prescribing Patterns in Newborns and Infants
Author(s) -
Marta Illueca,
Berhanu Alemayehu,
Nze Shoetan,
Hui-Ying Yang
Publication year - 2014
Publication title -
the journal of pediatric pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 15
eISSN - 2331-348X
pISSN - 1551-6776
DOI - 10.5863/1551-6776-19.4.283
Subject(s) - medicine , esomeprazole , gerd , pediatrics , proton pump inhibitor , medical record , emergency medicine , reflux , disease
In 2011, the Food and Drug Administration (FDA) approved intravenous esomeprazole 0.5 mg/day for children aged >1 month and oral esomeprazole for infants aged 1 month to <1 year at doses of 2.5, 5, and 10 mg based on weight. Prior to 2011, proton pump inhibitors (PPIs) were not approved for use in infants aged <1 year. This study determined PPI usage rates prior to the FDA approval among newborns and infants in both the inpatient and outpatient settings and compared PPI and histamine-2 receptor antagonist (H2RA) usage in the inpatient setting.